We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Nepafenac may reduce macular volume.
- Authors
Charters, Lynda; Miller, Daniel M.
- Abstract
The article discusses a study which showed that nepafenac, a topical nonsteroidal anti-inflammatory drug (NSAID) marketed by Alcon Laboratories as Nevanac, may decrease macular volume more rapidly after surgery to repair epiretinal membranes (ERM). Daniel M. Miller of the Cincinnati Eye Institute discusses the drug's benefit and safety profile. The decrease of the central subfield macular thickness by 10% and the macular volume by about 5% three months postoperatively is also noted.
- Subjects
NONSTEROIDAL anti-inflammatory agents; ALCON Laboratories Inc.; MILLER, Daniel M.; RETINAL diseases; EYE diseases
- Publication
Optometry Times, 2011, Vol 3, Issue 7, p22
- ISSN
0890-7080
- Publication type
Article